101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial

Frías, Juan P.; Auerbach, Pernille; Bajaj, Harpreet S.; Fukushima, Yasushi; Lingvay, Ildiko; Macura, Stanislava; Søndergaard, Anette L.; Tankova, Tsvetalina; Tentolouris, Nikolaοs; Buse, John B.

doi:10.2337/db21-101-or

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The latter study included pharmacokinetics and showed half‐life of 159–195 h, with a median tmax of 24–72 h which would be consistent with weekly administration of the amylin agonist (Enebo et al, 2021). A more recent phase 2 study has also confirmed the efficacy of combination cagrilintide with semaglutide leading to 15.6% weight reduction at 32 weeks relative to baseline, and with greater weight loss than each component alone (Frias et al, 2023).…”

Section: Introductionmentioning

confidence: 86%

Newer pharmacological interventions directed at gut hormones for obesity

Camilleri,

Acosta

2023

British J Pharmacology

View full text Add to dashboard Cite

The objective is to review the newer pharmacological interventions for obesity, specifically single, dual, and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP), and glucagon. There are several approved single or dual incretin agonists which are administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and experimental dual or triple incretin agonists. Other analogs of amylin, peptide YY, and oxyntomodulin, as well as a combination GLP1R agonist and GIPR antagonist are also being developed. Oral semaglutide (administered daily) is approved for type 2 diabetes and is on track for regulatory review for obesity. The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite. In the future, it is anticipated that small molecule GLP‐1 receptor agonists (e.g., oral danuglipron) will be developed. These pharmacological agents are having significant impact on glycemic control and obesity and their co‐morbidities.

show abstract

Section: Introductionmentioning

confidence: 86%

Newer pharmacological interventions directed at gut hormones for obesity

Camilleri,

Acosta

2023

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Glycated hemoglobin and body weight reductions are generally maintained with ongoing treatment [54,56,58,59,60,63,93]. Semaglutide 2.0 mg was superior to 1.0 mg in reducing glycated hemoglobin, with additional body weight loss and a similar safety profile [61], and dulaglutide 4.5 mg provided superior glycated hemoglobin reductions compared with 1.5 mg, with a similar safety profile [61]. Dulaglutide is now approved at additional doses of 3.0 mg and 4.5 mg if additional glycemic control is needed [27].…”

Section: Choosing a Glp-1ra -Efficacy And Tolerabilitymentioning

confidence: 97%

“…Most GLP-1RAs are injected, either daily or weekly. One GLP-1RA -semaglutide -is now available as a daily oral tablet [61], which may facilitate earlier GLP-1RA initiation by helping to overcome barriers in injection-naïve patients. Nevertheless, some patients may prefer a once-weekly injection to a daily tablet and innovations in injectable delivery devices are improving the ease of self-injection.…”

Section: Choosing a Glp-1ra -Mode Of Administration And Associated Co...mentioning

confidence: 99%

Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control

J¹,

Uusinarkaus²,

SP³

et al. 2023

jfammed

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is no longer considered solely a glucose-centric condition, but rather a chronic cardiometabolic disease that is linked to premature cardiovascular and renal complications and early death. Whereas previously, the level of glycemic control drove management decisions regarding treatment intensification, healthcare providers now have newer classes of agents that not only effectively lower glucose levels but also reduce the long-term risk of cardiovascular and renal complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) address several of the progressive multiorgan dysfunctions associated with T2D and a number of GLP-1RAs have been shown to reduce the risk of major adverse cardiovascular events in people with established cardiovascular disease or in those at high cardiovascular risk; GLP-1RAs (or a cardioprotective sodium-glucose cotransporter-2 inhibitor) should be considered in these high-risk patients regardless of their glycated hemoglobin goal attainment status. GLP-1RAs also facilitate substantial weight loss and there is some evidence that they may help to restore β-cell function and slow the decline of kidney function, although further studies are needed to confirm this.

show abstract

“…Glycated hemoglobin and body weight reductions are generally maintained with ongoing treatment [54,56,58,59,60,63,93]. Semaglutide 2.0 mg was superior to 1.0 mg in reducing glycated hemoglobin, with additional body weight loss and a similar safety profile [61], and dulaglutide 4.5 mg provided superior glycated hemoglobin reductions compared with 1.5 mg, with a similar safety profile [59]. Dulaglutide is now approved at additional doses of 3.0 mg and 4.5 mg if additional glycemic control is needed [27].…”

Section: Choosing a Glp-1ra -Efficacy And Tolerabilitymentioning

confidence: 97%

Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control

J¹,

Uusinarkaus²,

SP³

et al. 2022

jfammed

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is no longer considered solely a glucosecentric condition, but rather a chronic cardiometabolic disease that is linked to premature cardiovascular and renal complications and early death. Whereas previously, the level of glycemic control drove management decisions regarding treatment intensification, healthcare providers now have newer classes of agents that not only effectively lower glucose levels but also reduce the long-term risk of cardiovascular and renal complications. Glucagon-like peptide- 1 receptor agonists (GLP-1RAs) address several of the progressive multiorgan dysfunctions associated with T2D and a number of GLP-1RAs have been shown to reduce the risk of major adverse cardiovascular events in people with established cardiovascular disease or in those at high cardiovascular risk; GLP-1RAs (or a cardioprotective sodium-glucose cotransporter-2 inhibitor) should be considered in these high-risk patients regardless of their glycated hemoglobin goal attainment status. GLP-1RAs also facilitate substantial weight loss and there is some evidence that they may help to restore β-cell function and slow the decline of kidney function, although further studies are needed to confirm this.

show abstract

101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial

Cited by 10 publications

References 0 publications

Newer pharmacological interventions directed at gut hormones for obesity

Newer pharmacological interventions directed at gut hormones for obesity

Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control

Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control

Contact Info

Product

Resources

About